The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this ...
PRINCETON, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States ...
PRINCETON, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic ...
PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing function Phase 1/2 study is enrolling patients with advanced solid tumors that have a p53 ...
Enrollment remains on track in Phase 2 pivotal portion of PYNNACLE trial evaluating rezatapopt as monotherapy in platinum-resistant/refractory ovarian cancer patients with a TP53 Y220C mutation Cash, ...
PMV Pharmaceuticals Inc (NASDAQ:PMVP) announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple ...
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results